# Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

> **NCT02652455** · EARLY_PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 11 (actual)

## Conditions studied

- Melanoma (Skin)
- Skin Cancer

## Interventions

- **DRUG:** Nivolumab
- **PROCEDURE:** Surgery to Remove Tumor for Growth of TIL
- **DRUG:** CD137
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** TIL Infusion
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT02652455
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-08
- **Primary completion:** 2020-08-30
- **Final completion:** 2020-08-30
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-08-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02652455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02652455, "Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT02652455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*